For biotech founders · fundraising & BD partnering
Search-visible evidence rooms, mechanism and indication pages, and a literature-grounded AI layer (RAG over a vector-embedded public corpus) so investors and partners can orient fast—without you re-writing the same science brief every week.
The constraint is usually not weak science—it is weak discoverability and fragmented attribution. Evidence that should differentiate a company is scattered across channels that investors and partners do not reliably traverse in a single sitting.
Whether you are closing a round or opening partnering conversations, the constraint is the same: outsiders have to understand a complex program quickly—and believe you can carry it. BioticaBio combines public evidence pages with a corpus-backed AI layer so visibility is engineered, not improvised.
A structured map of where your technical story lives today, which concepts you own (and which you do not), and where evidence is redundant, missing, or mis-attributed—prioritized for investors and BD leads who are deciding whether to spend another hour on you.
A coherent set of public-facing pages—overview, mechanism, indication, comparator, authorities, and synthesis—so a busy associate or partnering scientist can move from question to proof without hunting across PDFs and scattered PubMed tabs.
Narratives that translate mechanism clarity into commercial legibility: what is novel, what is validated, and what clinical or translational context makes the program legible outside the specialist bubble.
Side-by-side framing against standard of care, relevant comparators, and category analogs so non-specialists can place the asset quickly—critical when every partnering thread starts with “how is this different?”
A careful map of KOLs, inventors, institutions, and third-party validators that should be associated with your claims—used to strengthen attribution and reduce “interesting science, unclear ownership” friction.
Operational reporting on indexing, queries, and on-site engagement using Search Console and analytics—so you can see whether the concepts you care about resolve to the pages you own.
A vector-embedded index of published research and curated public-domain sources, with retrieval-augmented generation so an AI agent can compress mechanism context, surface benchmarks, and keep answers tied to retrieved passages—built for the pace of fundraising and BD, not lab notebook search.
How the platform works →For founders in active raises and BD pushes: your program’s story should not depend on someone else re-reading the same fifty papers. We vector-embed published science and reputable public-domain sources—then run retrieval-augmented generation so an agent can brief mechanism, indication, and benchmark context in minutes, anchored in retrieved passages—not guesswork.
Architecture
Chunk → embed → index. Query → retrieve relevant passages → generate synthesis and comparisons (RAG). Your public evidence room and the wider literature stay in sync so visibility is a system—not a one-off deck.
Conferences and intros still matter—but partners and investors increasingly form views through asynchronous research. A digitally discoverable, objective, data-grounded narrative reduces friction in that window: it helps a busy evaluator understand what you claim, what is supported, and what to ask next.
Meetings compress trust formation, clarify ambiguity fast, and create momentum inside buying groups. For BD-heavy categories, that density is still a core part of how relationships start.
Third-party B2B research consistently emphasizes self-directed evaluation and the value of high-quality information and enablement—not generic promotion—when buyers are trying to understand capabilities and risk. The Sources list highlights representative work from Edelman–LinkedIn, Gartner, and McKinsey you can map to your own claims discipline and page design.
Search Console remains a practical operational layer for whether your public narrative is discoverable where people actually search.
An illustrative evidence-room structure for a scientifically interesting, commercially easy-to-misread target: IAIP in the context of necrotizing enterocolitis. The showcase demonstrates module design, narrative sequencing, and how attribution can be tightened without hype.
Showcase evidence room
Demonstrates mechanism, indication, comparator, authorities, and synthesis pages as a navigable unit—built to be read asynchronously by investors and BD leads who may not yet connect the biology to the company name.
Read the case studyA tight loop from diagnosis to assets to measurement—designed to stay maintainable inside your team and your agency workflow.
Locate where evidence lives, where company-to-concept linkage breaks, and which entities and queries matter for your next 12–18 months.
Ship investor-legible pages and summaries that preserve technical accuracy while reducing cognitive load—mechanism, indication, comparator, authorities, synthesis.
Track indexing, impressions, and engagement as operational signals. Interpret trends cautiously; refine content when the data shows confusion or gaps.
Share your program, audience, and constraints. You will get a practical read on discoverability gaps and what an evidence room would need to cover first.